Elevating Understanding and Management of Hypertriglyceridemia: From Risk Factor to Novel Therapeutic Target

Published: 25 March 2024

  • Views:

    Views Icon 375
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This microlearning series aims to provide guidance on how to identify, manage, and treat hypertriglyceridemia (HTG) in your patients and improving patient outcomes.

 

The programme is aimed to improve understanding of HTG as a risk factor for acute and chronic illness, address challenges of diagnosing and treating elevated TG levels and review latest data for emerging therapies. 

 

Guided by the expertise of renowned leaders in the field, including Dr Christie Ballantyne (Baylor College of Medicine, Texas, US) as programme chair, who is accompanied by Dr Robert Eckel (University of Colorado, Colorado, US), Prof Ioanna Gouni-Berthold (University of Cologne, Cologne, DE) and Dr Nicholas Marston (Brigham and Women’s Hospital, Boston, US), this series comprises five succinct sessions designed to revolutionise your approach to HTG management.

 

The full series of this programme is available as a course to earn 1.00 AMA PRA Credit.

 

This programme is supported by an unrestricted educational grant from Ionis Pharmaceuticals.

Key Learning Objectives

  • Understand HTG as a risk factor for acute and chronic illness
  • Describe current guideline directed management of HTG
  • Recognise the gaps and challenges present in current guideline directed management of HTG
  • Recall emerging trial data for novel pharmacological targets
  • Use guidelines, trial data & expert opinion to develop individualised treatment strategies for high-risk patients

Target Audience

  • Cardiologists
  • Lipidologists
  • Other Allied HCPs

More from this programme

Part 1

Hypertriglyceridemia: A Risk Factor for Acute & Chronic Illness

In this first part, Dr Eckel explores hypertriglyceridemia as a risk factor for both acute & chronic illness.

Part 2

Current Guideline-Directed Approach to Hypertriglyceridemia

In this second part, Prof Gouni-Berthold presents some of the guidelines and looks at management strategies and treatment goals. 

Part 3

Gaps & Challenges within Current Approach

In this third part, Dr Ballantyne touches on the remaining gaps and challenges. 

Part 4

Novel Pharmacological Management of HTG

In this fourth part, Dr Marston guides us through various pharmacological management options for HTG. 

Part 5

Discussion: Optimal Approach to HTG Diagnosis & Management

In this final part, the panel share their thoughts and guidance on some really important practical points on the management of HTG. 

Faculty Biographies

Christie Ballantyne

Christie Ballantyne

Chief of Cardiovascular Research and Director of the Center for Cardiometabolic Disease Prevention

Dr Christie Ballantyne is the Chief of Cardiovascular Research, Director of the Center for Cardiometabolic Disease Prevention, and Professor of Medicine at Baylor College of Medicine in Texas, US.

He received his MD from Baylor College of Medicine and performed both his internal medicine residency at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.

Dr Ballantyne is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte- endothelial interactions,…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.